Drug Detail

Information about Durvalumab + Trememimumab

Generic Name	Durvalumab + Trememimumab
IND
Brand Name (US)
Manufacturer
Drug Type
Delivery	Intravenous
Approval Status
Indications
Overall Strategy	Immune system
Strategy	Immune checkpoint inhibitor
Drug Category	PD-L1 + CTLA-4 inhibitor

Links
	Antonia S, Goldberg SB, Balmanoukian A, et al. Safety and antitumor activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol. 2016;17(3):299-308.

Trials of this drug
	Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes

Trial results